1 | designs | 3,756 |
2 | projects | 627 |
3 | premises | 114 |
4 | protections | 57 |
5 | cookstoves | 15 |
6 | cruises | 14 |
7 | ventures | 12 |
8 | buckypapers | 7 |
9 | morphspaces | 7 |
10 | 'up | 6 |
11 | superpixels | 6 |
12 | intents | 5 |
13 | lineups | 5 |
14 | pavements | 5 |
15 | quadruplexes | 5 |
16 | 2/high | 4 |
17 | 1-mild/moderate | 3 |
18 | 2-ocs | 3 |
19 | 2/low | 3 |
20 | bia-2093-203 | 3 |
21 | intervention.we | 3 |
22 | post-pvr | 3 |
23 | s7823 | 3 |
24 | surmises | 3 |
25 | 1222.11 | 2 |
26 | 40983 | 2 |
27 | antilipolysis | 2 |
28 | apiece | 2 |
29 | astrazeneca-sponsored | 2 |
30 | b253 | 2 |
31 | benensis | 2 |
32 | bia-2093-205 | 2 |
33 | bulaquine | 2 |
34 | cotwin | 2 |
35 | cycloisomerase | 2 |
36 | h9c-mc-bbdk | 2 |
37 | harow | 2 |
38 | hydrophobins | 2 |
39 | jp19959 | 2 |
40 | mantras | 2 |
41 | matris | 2 |
42 | n-ylides | 2 |
43 | nct01005888 | 2 |
44 | self-importance | 2 |
45 | turra | 2 |
46 | '* | 1 |
47 | -19.03 | 1 |
48 | 0099 | 1 |
49 | 1.5/g/kg | 1 |
50 | 134006 | 1 |
51 | 22961 | 1 |
52 | 22:507-511 | 1 |
53 | 24:181-186 | 1 |
54 | 27:123-124 | 1 |
55 | 30,853 | 1 |
56 | 34:333-340 | 1 |
57 | 43:657-662 | 1 |
58 | 58831/32 | 1 |
59 | 97-14 | 1 |
60 | a5207 | 1 |
61 | accural | 1 |
62 | ahod0031 | 1 |
63 | aml-bfm87 | 1 |
64 | ansaldo | 1 |
65 | arm.overall | 1 |
66 | arm/sex | 1 |
67 | asct0031 | 1 |
68 | assistant-directed | 1 |
69 | authorities-would | 1 |
70 | authors.in | 1 |
71 | bia-2093-302 | 1 |
72 | c208 | 1 |
73 | centers/surgeons | 1 |
74 | centre-riyadh | 1 |
75 | comprised-center | 1 |
76 | contact-hypersensitivity | 1 |
77 | criterid | 1 |
78 | data/information/evidence | 1 |
79 | db2113359 | 1 |
80 | desactivation | 1 |
81 | design/methodology | 1 |
82 | discs/exl-695 | 1 |
83 | drug/procedure | 1 |
84 | dusp7/mkpx | 1 |
85 | epis | 1 |
86 | erss | 1 |
87 | faster-onset | 1 |
88 | foundation-flanders | 1 |
89 | gliders | 1 |
90 | group-nurses | 1 |
91 | h2303 | 1 |
92 | h2304 | 1 |
93 | h8y-mc-hbbm | 1 |
94 | hands-on-tool | 1 |
95 | hatchery/nursery | 1 |
96 | implications/limitations | 1 |
97 | kiosks | 1 |
98 | linearizations | 1 |
99 | linkers-one | 1 |
100 | lndose | 1 |
101 | lpa112025 | 1 |
102 | material=test | 1 |
103 | methodologyreports | 1 |
104 | methotrexate-fluorouracil | 1 |
105 | mother-child-admission | 1 |
106 | nct0094398 | 1 |
107 | nevirapine/placebo | 1 |
108 | nickel-chelating | 1 |
109 | no.15 | 1 |
110 | observationa | 1 |
111 | ohrs | 1 |
112 | overfrustrated | 1 |
113 | pa-012 | 1 |
114 | plastrons | 1 |
115 | population/design | 1 |
116 | procedures/concepts | 1 |
117 | quasi-impossible | 1 |
118 | r-banding | 1 |
119 | radiation-protocols | 1 |
120 | regimen/agent | 1 |
121 | registe | 1 |
122 | replicases | 1 |
123 | resources/clinical | 1 |
124 | rn1001-0042 | 1 |
125 | rs769391 | 1 |
126 | sub-lingual | 1 |
127 | support/funding | 1 |
128 | surgeon-scientist | 1 |
129 | therapy-using | 1 |
130 | tiefenbrunn | 1 |
131 | treatments/horse | 1 |
132 | videodance | 1 |
133 | vincristine-doxorubicin-cyclophosphamide | 1 |
134 | μ1,1- | 1 |
1 | '* | 1 |
2 | 'up | 6 |
3 | -19.03 | 1 |
4 | 0099 | 1 |
5 | 1-mild/moderate | 3 |
6 | 1.5/g/kg | 1 |
7 | 1222.11 | 2 |
8 | 134006 | 1 |
9 | 2-ocs | 3 |
10 | 2/high | 4 |
11 | 2/low | 3 |
12 | 22961 | 1 |
13 | 22:507-511 | 1 |
14 | 24:181-186 | 1 |
15 | 27:123-124 | 1 |
16 | 30,853 | 1 |
17 | 34:333-340 | 1 |
18 | 40983 | 2 |
19 | 43:657-662 | 1 |
20 | 58831/32 | 1 |
21 | 97-14 | 1 |
22 | a5207 | 1 |
23 | accural | 1 |
24 | ahod0031 | 1 |
25 | aml-bfm87 | 1 |
26 | ansaldo | 1 |
27 | antilipolysis | 2 |
28 | apiece | 2 |
29 | arm.overall | 1 |
30 | arm/sex | 1 |
31 | asct0031 | 1 |
32 | assistant-directed | 1 |
33 | astrazeneca-sponsored | 2 |
34 | authorities-would | 1 |
35 | authors.in | 1 |
36 | b253 | 2 |
37 | benensis | 2 |
38 | bia-2093-203 | 3 |
39 | bia-2093-205 | 2 |
40 | bia-2093-302 | 1 |
41 | buckypapers | 7 |
42 | bulaquine | 2 |
43 | c208 | 1 |
44 | centers/surgeons | 1 |
45 | centre-riyadh | 1 |
46 | comprised-center | 1 |
47 | contact-hypersensitivity | 1 |
48 | cookstoves | 15 |
49 | cotwin | 2 |
50 | criterid | 1 |
51 | cruises | 14 |
52 | cycloisomerase | 2 |
53 | data/information/evidence | 1 |
54 | db2113359 | 1 |
55 | desactivation | 1 |
56 | design/methodology | 1 |
57 | designs | 3,756 |
58 | discs/exl-695 | 1 |
59 | drug/procedure | 1 |
60 | dusp7/mkpx | 1 |
61 | epis | 1 |
62 | erss | 1 |
63 | faster-onset | 1 |
64 | foundation-flanders | 1 |
65 | gliders | 1 |
66 | group-nurses | 1 |
67 | h2303 | 1 |
68 | h2304 | 1 |
69 | h8y-mc-hbbm | 1 |
70 | h9c-mc-bbdk | 2 |
71 | hands-on-tool | 1 |
72 | harow | 2 |
73 | hatchery/nursery | 1 |
74 | hydrophobins | 2 |
75 | implications/limitations | 1 |
76 | intents | 5 |
77 | intervention.we | 3 |
78 | jp19959 | 2 |
79 | kiosks | 1 |
80 | linearizations | 1 |
81 | lineups | 5 |
82 | linkers-one | 1 |
83 | lndose | 1 |
84 | lpa112025 | 1 |
85 | mantras | 2 |
86 | material=test | 1 |
87 | matris | 2 |
88 | methodologyreports | 1 |
89 | methotrexate-fluorouracil | 1 |
90 | morphspaces | 7 |
91 | mother-child-admission | 1 |
92 | n-ylides | 2 |
93 | nct0094398 | 1 |
94 | nct01005888 | 2 |
95 | nevirapine/placebo | 1 |
96 | nickel-chelating | 1 |
97 | no.15 | 1 |
98 | observationa | 1 |
99 | ohrs | 1 |
100 | overfrustrated | 1 |
101 | pa-012 | 1 |
102 | pavements | 5 |
103 | plastrons | 1 |
104 | population/design | 1 |
105 | post-pvr | 3 |
106 | premises | 114 |
107 | procedures/concepts | 1 |
108 | projects | 627 |
109 | protections | 57 |
110 | quadruplexes | 5 |
111 | quasi-impossible | 1 |
112 | r-banding | 1 |
113 | radiation-protocols | 1 |
114 | regimen/agent | 1 |
115 | registe | 1 |
116 | replicases | 1 |
117 | resources/clinical | 1 |
118 | rn1001-0042 | 1 |
119 | rs769391 | 1 |
120 | s7823 | 3 |
121 | self-importance | 2 |
122 | sub-lingual | 1 |
123 | superpixels | 6 |
124 | support/funding | 1 |
125 | surgeon-scientist | 1 |
126 | surmises | 3 |
127 | therapy-using | 1 |
128 | tiefenbrunn | 1 |
129 | treatments/horse | 1 |
130 | turra | 2 |
131 | ventures | 12 |
132 | videodance | 1 |
133 | vincristine-doxorubicin-cyclophosphamide | 1 |
134 | μ1,1- | 1 |
1 | '* | 1 |
2 | μ1,1- | 1 |
3 | 34:333-340 | 1 |
4 | 1222.11 | 2 |
5 | 22:507-511 | 1 |
6 | ahod0031 | 1 |
7 | asct0031 | 1 |
8 | 22961 | 1 |
9 | rs769391 | 1 |
10 | bia-2093-302 | 1 |
11 | pa-012 | 1 |
12 | 58831/32 | 1 |
13 | rn1001-0042 | 1 |
14 | 43:657-662 | 1 |
15 | -19.03 | 1 |
16 | bia-2093-203 | 3 |
17 | h2303 | 1 |
18 | s7823 | 3 |
19 | b253 | 2 |
20 | 30,853 | 1 |
21 | 40983 | 2 |
22 | h2304 | 1 |
23 | 97-14 | 1 |
24 | 27:123-124 | 1 |
25 | bia-2093-205 | 2 |
26 | no.15 | 1 |
27 | lpa112025 | 1 |
28 | discs/exl-695 | 1 |
29 | 134006 | 1 |
30 | 24:181-186 | 1 |
31 | a5207 | 1 |
32 | aml-bfm87 | 1 |
33 | c208 | 1 |
34 | nct01005888 | 2 |
35 | nct0094398 | 1 |
36 | db2113359 | 1 |
37 | jp19959 | 2 |
38 | 0099 | 1 |
39 | observationa | 1 |
40 | turra | 2 |
41 | astrazeneca-sponsored | 2 |
42 | overfrustrated | 1 |
43 | assistant-directed | 1 |
44 | criterid | 1 |
45 | authorities-would | 1 |
46 | apiece | 2 |
47 | videodance | 1 |
48 | self-importance | 2 |
49 | data/information/evidence | 1 |
50 | vincristine-doxorubicin-cyclophosphamide | 1 |
51 | quasi-impossible | 1 |
52 | bulaquine | 2 |
53 | linkers-one | 1 |
54 | drug/procedure | 1 |
55 | cycloisomerase | 2 |
56 | lndose | 1 |
57 | treatments/horse | 1 |
58 | 1-mild/moderate | 3 |
59 | registe | 1 |
60 | intervention.we | 3 |
61 | 1.5/g/kg | 1 |
62 | r-banding | 1 |
63 | support/funding | 1 |
64 | therapy-using | 1 |
65 | nickel-chelating | 1 |
66 | centre-riyadh | 1 |
67 | 2/high | 4 |
68 | h9c-mc-bbdk | 2 |
69 | resources/clinical | 1 |
70 | accural | 1 |
71 | sub-lingual | 1 |
72 | methotrexate-fluorouracil | 1 |
73 | arm.overall | 1 |
74 | hands-on-tool | 1 |
75 | h8y-mc-hbbm | 1 |
76 | population/design | 1 |
77 | authors.in | 1 |
78 | cotwin | 2 |
79 | tiefenbrunn | 1 |
80 | mother-child-admission | 1 |
81 | desactivation | 1 |
82 | nevirapine/placebo | 1 |
83 | ansaldo | 1 |
84 | 'up | 6 |
85 | comprised-center | 1 |
86 | post-pvr | 3 |
87 | mantras | 2 |
88 | 2-ocs | 3 |
89 | morphspaces | 7 |
90 | n-ylides | 2 |
91 | ventures | 12 |
92 | replicases | 1 |
93 | premises | 114 |
94 | surmises | 3 |
95 | cruises | 14 |
96 | group-nurses | 1 |
97 | cookstoves | 15 |
98 | quadruplexes | 5 |
99 | epis | 1 |
100 | matris | 2 |
101 | benensis | 2 |
102 | antilipolysis | 2 |
103 | kiosks | 1 |
104 | superpixels | 6 |
105 | radiation-protocols | 1 |
106 | designs | 3,756 |
107 | hydrophobins | 2 |
108 | centers/surgeons | 1 |
109 | implications/limitations | 1 |
110 | linearizations | 1 |
111 | protections | 57 |
112 | plastrons | 1 |
113 | lineups | 5 |
114 | gliders | 1 |
115 | foundation-flanders | 1 |
116 | buckypapers | 7 |
117 | ohrs | 1 |
118 | erss | 1 |
119 | projects | 627 |
120 | pavements | 5 |
121 | intents | 5 |
122 | procedures/concepts | 1 |
123 | methodologyreports | 1 |
124 | faster-onset | 1 |
125 | regimen/agent | 1 |
126 | material=test | 1 |
127 | surgeon-scientist | 1 |
128 | 2/low | 3 |
129 | harow | 2 |
130 | arm/sex | 1 |
131 | dusp7/mkpx | 1 |
132 | design/methodology | 1 |
133 | hatchery/nursery | 1 |
134 | contact-hypersensitivity | 1 |